Fanconi Syndrome induced by the use of Tenofovir in co-infected person HIV-multiresistant Hepatitis B virus

Main Article Content

Jéssica Freitas Planello
Daniela Chinelato Marcelino
Rafael Cypriani
Bernardino Geraldo Alves Souto


Introduction: HIV-HBV coinfection is common and Tenofovir (TDF) is the drug of choice because it acts against both viruses at the same time. However, about 1% of cases can induce Fanconi Syndrome, leading to kidney failure. Case report: On an HIV-HBV co-infected man, with controlled HIV replication, Hepatitis B virus was resistant to all available drugs, except TDF. Twenty-two months after antiretroviral treatment compound with that drug, which controlled both viruses’ replication at the same time, he developed renal insufficiency with loss of absorbable solutes at proximal convoluted tubule, diagnosed as Fanconi Syndrome induced by TDF. Facing the dilemma of suspending the TDF for preserving the kidney and to allow the replication of the HBV, or to keep the TDF for preserving the liver and to accept the renal degeneration, we chose to balance the treatment according to the best possible equilibrium between HBV replication and kidney preservation, adjusting the posology of medications according to clinical and laboratorial indicators of liver risk and renal function. Conclusion: The only therapeutic option currently available to coinfected people by HIV-HBV who develop renal failure by the TDF consists on adjustment of the dose of the TDF according creatinine clearance, symptomatic treatment, replacement of urinary losses which have metabolic impact, and clinical and laboratory monitoring of the HIV infection, Hepatitis B, Renal insufficiency and Bone remodeling.


Download data is not yet available.

Article Details

How to Cite
Planello, J. F., Marcelino, D. C., Cypriani, R., & Souto, B. G. A. (2016). Fanconi Syndrome induced by the use of Tenofovir in co-infected person HIV-multiresistant Hepatitis B virus. ABCS Health Sciences, 41(1).


Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para o tratamento da hepatite viral crônica B e coinfecções. Brasília: Ministério da Saúde;2010. p.132.

Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619-27.

Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689-96.

Canale D. Mecanismos de lesão renal em ratos com deficiência de vitamina D submetidos ao tratamento com Tenofovir. Tese (Doutorado) – Faculdade de Medicina da Universidade de São Paulo. São Paulo: 2014. p.104.

Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in hiv-infected patients. AIDS Rev. 2012;14(3);179-87.

Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49(8):3361-6.

Lacy CF, Armstrong LL, Goldman MP, Lance LL. Medicamentos Lexi-Comp Manole: uma fonte abrangente para médicos e profissionais de saúde. Barueri: Manole; 2009. p.1269.

Barbosa TC. Resistência ao adefovir, entecavir e telbivudina no tratamento da hepatite B crônica. Monografia (Conclusão de Curso) – Universidade Federal da Bahia. Salvador: 2013. p.38.

Gatanaga H, Tachikawa N, Kikuchi Y, Teruya K, Genka I, Honda M, et al. Urinary beta 2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22(8):744-8.

Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2013;28(7):1011-23.

Liborio AB, Andrade L, Pereira LV, Sanches TR, Shimizu MH, Seguro AC. Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int. 2008;74(7):910-8.

Bam R, Yant S, Cihla T. Tenofovir alafenamide (GS-7340) is not a substrate for renal organic anion transporters (OAT) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014; Abstract.

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al. Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Deficiency? Antimicrob Agents Chemother. 2013;57(11): 5619-28.

Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, et al. Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2012:54(7):1013-25.

Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. Hospital das Clínicas. Grupo Integrado de Transplante de Fígado [Internet]. Transplante de Fígado: Tx Fig Ribeirão: Protocolo. Disponível em Acesso em: 26 fev. 2015.